Related Experiment Video
Updated: May 15, 2025

Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran
Published on: November 18, 2022
Per- and polyfluoroalkyl substances mixture impairs intestinal barrier function through microbiota-derived
Tingting Lin1, Luyang He2, Sishuo Liu3
1Institute of Environmental Medicine, Zhejiang University School of Public Health, Hangzhou 310058, China; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Abstract:
Per- and polyfluoroalkyl substances (PFASs) are persistent environmental pollutants linked to various health risks, including intestinal disorders. However, the effect of real-world PFASs mixture on intestinal health remains unclear. Therefore, this study aimed to investigate the effects of a PFASs mixture by mimicking the exposure composition in a population on intestinal homeostasis in rats. Although the colon showed no significant morphological alterations, transcriptomic analysis revealed dose-dependent changes in gene expression levels related to cell-cell and tight junctions. Immunofluorescence and immunohistochemistry further confirmed these findings, demonstrating a dose-dependent decrease in key tight junction proteins, occludin and claudin-1, in the colonic epithelium. Integrative analysis revealed that PFASs mixture exposure disrupted the growth and metabolism of gut bacteria, such as Ruminococcus, leading to increased production of 21-deoxycortisol (21-DF). 21-DF inhibited cortisol to cortisone conversion, elevating cortisol levels in intestinal epithelial cells. Consequently, the increased cortisol levels suppressed the expression of tight junction proteins and disrupted the intestinal barrier function. Our findings provide novel insights into the underlying mechanisms by which real-world PFASs mixture disrupt intestinal barrier function through the gut microbiome-metabolome-epithelial cell axis, highlighting the need to consider the complex interplay between environmental pollutants, gut microbiota, and host health in risk assessment and development of intervention strategies.
Related Concept Videos
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD

